Biotech Values

[DewDiligence]

>MRK did say they expect 5 more in pivotal studies by 2012. epo is just first.<

Understood; however, the other four could also be from the “easy” FoB group mentioned in my prior post.

What will separate the men from the boys in the FoB arena are two things, IMO:

• The ability to make complex proteins such as mAbs that are sufficiently close to their branded counterparts to qualify for an abbreviated regulatory pathway.

• The ability to characterize branded drugs completely, allowing fully substitutable biogenerics to be sold with little or no marketing.

It’s unclear to me whether MRK possesses either of these skills.